Subscriber access provided by CORNELL UNIVERSITY LIBRARY
Article
Delivery of Dual Drug Loaded Lipid Based Nanoparticles Across Blood Brain Barrier Impart Enhanced Neuroprotection in a Rotenone Induced Mouse Model of Parkinson’s Disease Paromita Kundu, Manasi Das, Kalpalata Tripathy, and Sanjeeb K Sahoo ACS Chem. Neurosci., Just Accepted Manuscript • DOI: 10.1021/acschemneuro.6b00207 • Publication Date (Web): 19 Sep 2016 Downloaded from http://pubs.acs.org on September 20, 2016
Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.
ACS Chemical Neuroscience is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.
Page 1 of 41
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
ACS Chemical Neuroscience
1
Delivery of Dual Drug Loaded Lipid Based Nanoparticles Across Blood Brain Barrier
2
Impart Enhanced Neuroprotection in a Rotenone Induced Mouse Model of Parkinson’s
3
Disease
4
Paromita Kundu¶, Manasi Das¶, Kalpalata Tripathyǂ, Sanjeeb K Sahoo*, ¶
5
¶
Institute of Life Sciences, Nalco Square, Bhubaneswar, India, 751023
6
7
ǂ
Department of Pathology, Shri Ramachandra Bhanj Medical College, Cuttack, India, 753007
8 9
ABSTRACT: Parkinson disease (PD) is the most widespread form of dementia where there
10
is an age related degeneration of dopaminergic neurons in the substantia nigra region of the
11
brain. Accumulation of α-synuclein (αS) protein aggregate, mitochondrial dysfunction,
12
oxidative stress and neuronal cell death are the pathological hallmark of PD. In this context,
13
amalgamation of curcumin and piperine having profound cognitive properties and antioxidant
14
activity seems beneficial. However, blood brain barrier (BBB) is the major impediment for
15
delivery of neurotherapeutics to the brain. The present study involves formulation of
16
curcumin and piperine co-loaded glyceryl monooleate (GMO) nanoparticles coated with
17
various surfactants with a view to enhance the bioavailability of curcumin, penetration of
18
both drugs to the brain tissue crossing the BBB and to enhance the anti-parkinsonism effect
19
of both drugs in a single platform. In vitro results demonstrated augmented inhibition of αS
20
protein into oligomers and fibrils, reduced rotenone induced toxicity, oxidative stress,
21
apoptosis and activation of autophagic pathway by dual drug loaded NPs compared to native
22
counterpart. Further, in vivo studies revealed that our formulated dual drug loaded NPs were
23
able to cross BBB, rescued the rotenone induced motor coordination impairment and
24
restrained dopaminergic neuronal degeneration in a PD mice model. 1 ACS Paragon Plus Environment
ACS Chemical Neuroscience
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 2 of 41
25 26
Graphic for the Table of Contents 27 28 29 30 31 32 33 34 35
36 37 38 39
KEYWORDS: Parkinson's disease, α-synuclein, blood brain barrier, lipid based nanoparticles, curcumin, piperine
40
Parkinson’s
disease
(PD)
is
the
second
most
prevalent
41
INTRODUCTION:
42
neurodegenerative disorder characterized by progressive loss of dopaminergic neurons of
43
substantia nigra and subsequent deprivation of dopamine in the basal ganglia.
44
patient’s encounters severe physical impairment and the major cardinal symptoms of the
45
disease include resting tremors, bradykinesia, postural instability and muscular rigidity.
46
Numerous aetiological causes have been linked to PD, including genetic mutations and
47
environmental toxins, but the main reason of cell death remains obscure. Abnormal
48
accumulations of aggregated α-synuclein (αS) proteins, high load of oxidative stress,
49
mitochondrial dysfunction and impaired apoptosis machinery are some of the potential
50
unifying factor in the aetiopathogenesis of the disease. 2, 3 Treatment of PD has been a major
51
challenge to the neurologist because treatment strategies have been mostly symptomatic and 2 ACS Paragon Plus Environment
1
The PD
1
Page 3 of 41
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
ACS Chemical Neuroscience
52
the mainstay of treatment aims at dopamine replacement therapy using drugs such as
53
levodopa, dopamine receptor agonist, anti-cholinergic agent etc. for managing the motor
54
disability.
55
neurodegeneration of dopaminergic neurons with long term treatment curtails the therapeutic
56
implementation of above conventional agents clinically.
57
aspects of cognition along with disabling motor fluctuations and dyskinesia are still at par.
58
The current limitations of conventional medicine has led in search for a more holistic
59
approach that can prevent neurodegeneration, modulate multiple molecular events and
60
symptomatic features and also impart minimal side effect for the effective PD treatment.
4
However, the drug induced side effects and inability to prevent
5, 6
Further, treatment on specific
61
In recent years, herbal drugs have received considerable interest because of the broad
62
spectrum of pharmacological properties that can be explored for the clinical management of
63
PD. Studies have strongly indicated that the herbal drug curcumin effectively counteracts the
64
molecular events of PD including oxidative stress, deregulated mitochondrial function,
65
aberrant apoptosis event, αS aggregation into oligomers and fibrils in vitro and also restores
66
motor impairment and attenuate loss of dopaminergic neurons in animal models of PD.
67
Though curcumin is a potent drug with high therapeutic value, yet its clinical efficacy in
68
various in vivo studies is marred because of its poor aqueous solubility, rapid metabolism and
69
inadequate tissue absorption, which severely curtails its bioavailability. 10 To this end, use of
70
adjuvants like piperine to improve the bioavailability of curcumin has been well explored
71
through oral route of administration by diverse research groups.
72
explored piperine as a bioavailability enhancer (inhibiting hepatic and intestinal
73
glucoronidation process) to improve the bioavailability of curcumin in preclinical studies and
74
studies conducted on human volunteers.
75
neuroprotective effect of piperine by counteracting the high load of oxidative stress,
76
mitochondrial dysfunction, and attenuating apoptosis in diverse in vitro and in vivo PD
14
11-13
7-9
Shoba et al. have
Further, mounting evidence also narrates the
3 ACS Paragon Plus Environment
ACS Chemical Neuroscience
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 4 of 41
77
disease model. 15, 16 Thus, amalgamating the therapeutic potential of curcumin and piperine in
78
a combinational approach, in which piperine will help to alleviate the bioavailability of
79
curcumin at the same time both the drugs will exhibit anti-parkinsonism effect by modulating
80
above unifying factors associated with the aetiopathogenesis of the disease, represents a
81
rational strategy.
82
However, delivery of both the drugs at a salutary level to exert therapeutic efficacy to
83
the brain tissue simultaneously to achieve an additive or synergistic effect is a challenging
84
task because of their inability to cross the highly selective blood-brain barrier (BBB)
85
separating the central nervous system (CNS) from systemic circulation. Challenges
86
associated with drug delivery to the CNS have fostered in the development of various
87
nanotechnology based delivery vehicle to enhance the transport of drugs from blood to the
88
brain.
89
crossing BBB at the same time to improve the limitations associated with conventional
90
regimens seems promising for effective PD management. Among the various nanoparticles
91
(NPs) regimes available, lipid based NPs has received much attention as potent carrier system
92
for CNS delivery because of its lipophilic nature, biocompatibility, biodegradability, and
93
having size in the nanometer range (10-200 nm), which allows them to readily cross the tight
94
endothelial cells of BBB.
95
efficiencies, controlled drug release profile, improved drug bioavailability and augmented
96
tissue distribution.
97
amphiphilic biocompatible lipid has gained special interest to formulate lipid based
98
nanoparticles because of the ability to enhance the bioavailability of encapsulated drugs. 22-24
99
Recently, we have developed a GMO based nanoformulation for delivery of anticancer drug
17, 18
Therefore, use of nanodelivery systems to deliver multiple therapeutic agents by
21
19, 20
Further, lipid based NPs also demonstrates high drug loading
In this context, glycerylmonooleate (GMO) a self-assembling
25
100
thereby emphasizing the scope of such GMO based NPs for CNS delivery.
101
surfactants like Pluronic F-68 and Vitamin E D-α-Tocopherol polyethylene glycol 1000 4 ACS Paragon Plus Environment
Further, use of
Page 5 of 41
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
ACS Chemical Neuroscience
102
succinate (vitamin E-TPGS) coated NPs has proven to be highly effective in delivering drugs
103
across the BBB. 26-28
104
With the above concept, the rationale of the present study was to formulate curcumin
105
and piperine loaded GMO based dual drug loaded NPs blended with surfactants such as
106
Pluronic F-68 and vitamin E-TPGS with a view to enhance the bioavailability of curcumin,
107
penetration of both the drugs to the brain tissue crossing the BBB and to achieve the
108
combinational anti-parkinsonism effect of both drugs in a single platform. Our results
109
demonstrated that curcumin when used in combination with piperine in nanoformulation
110
inhibited the aggregation of αS protein into oligomers and fibrils in vitro and also reduced
111
rotenone induced cell death in PC12 cells via decreasing the oxidative stress, apoptosis and
112
enhancing the autophagic activity. Further, our dual drug loaded NPs enhanced the oral
113
bioavailability of curcumin and also efficiently crossed the BBB to deliver the drugs into the
114
brain tissue and eventually rescued rotenone induced motor coordination impairment and
115
restrained dopaminergic neuronal degeneration in a PD mice model.
116
RESULTS AND DISCUSSION
117
Increase in incidence of PD at an alarming rate have raised major public health concern and is
118
expected to become a major cause of disability worldwide.
119
disease, an effective treatment strategy for preventing or curing of the disease is a call of the
120
hour. Further, BBB the bottle neck for the delivery of neurotherapeutics to the brain has been
121
a major limiting factor for the treatment of PD. 30 From the last few years, attention has been
122
turning towards the use of various dietary antioxidants for the treatment of PD because of
123
their potential neuroprotective properties. However, since most of these antioxidant
124
compounds do not cross the BBB, an ample salutary level does not reach to the brain to exert
125
considerable pharmacological effect. Despite copious research on CNS drug delivery
126
strategies, a very few of them has reached a phase of safe and effective human application.
29
5 ACS Paragon Plus Environment
Given the enormity of the
ACS Chemical Neuroscience
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 6 of 41
127
For the pace of innovation, the field of nanotechnology has opened new avenues and
128
prospects for delivering therapeutic payload crossing the BBB. 31 To this end, with an aim to
129
achieve a combinational therapeutic strategy enabling delivery of high therapeutic payload
130
crossing BBB at disease site in a sustained manner and facilitating symptomatic and
131
neuroprotective effect, in the present investigation, we have formulated (curcumin and
132
piperine) loaded lipid based nanoformulation blended with surfactants and studied its
133
therapeutic efficacy for PD treatment in cellular model, PC12 cells. The above cells responds
134
towards Nerve Growth Factor (NGF) that convert the cells from proliferating chromaffin-like
135
cells to non-dividing sympathetic-neuron-like cells with electrical excitability and sensitivity
136
towards neurotoxin rotenone in inducing neuronal degeneration, make it a convenient in vitro
137
model to study causes and possible treatments for PD.
138
formulated dual drug loaded NPs was also studied in a rotenone induced mouse PD model.
32
Further, the efficacy of our
139
Preparation and Characterization of (Curcumin and/or Piperine) Loaded NPs.
140
In the present study, we have formulated a GMO based NPs surface coated with surfactants
141
F-68 and vitamin E TPGS. Previously, our group has shown that GMO could be
142
advantageous in helping the NPs to cross the BBB. 24 Further, use of surfactants like F-68 and
143
vitamin E TPGS has proven to be highly effective in delivering drug across the BBB.
144
Recently, Kulkarni et al. has explored this strategy where surface coating of their polymeric
145
NPs by TPGS have dramatically influenced the NPs to deliver drug across the gastrointestinal
146
barrier and BBB.
147
where surface coating of poly(lactic-co-glycolic acid) (PLGA) NPs by surfactants like
148
poloxamer enabled the delivery of drugs into the brain.
149
suggest that due to lipophilic nature, lipid based nanoparticle has a natural tendency to cross
150
BBB and its small particle size facilitates effective reticuloendothelial system (RES) escape,
151
thereby increasing the chance of contact with BBB and for the drug to be taken up by the
27
26
Similar kind of studies have also been conducted by Gelperina et al.
28
Further, numerous investigations
6 ACS Paragon Plus Environment
Page 7 of 41
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
ACS Chemical Neuroscience
152
brain. 19, 20 Our formulated NPs also showed a size in the range of 93 ± 11 nm as evident from
153
Dynamic light scattering (DLS) analysis (Figure 1A) with negative zeta potential -30.9 ± 0.88
154
mV. The nanometer size of the formulated lipid NPs was further authenticated by
155
Transmission electron microscope (TEM) analysis (Figure 1B), which showed that the NPs
156
were of ~ 60 nm size. Size of NPs as measured by DLS was higher than the size observed in
157
TEM analysis, which may be attributed to the state of NPs used for measurement. DLS
158
analysis measures the hydrodynamic diameter of particles (consisted of particle core along
159
with solvent layer attached to the particle) present in a liquid suspension whereas, TEM
160
analysis measures the area of core of dry particle. 33 Similar pattern of size difference of NPs
161
measured through TEM and DLS was also evident in our previous study.
162
and smooth surface of dual drug loaded NPs was confirmed by Atomic force microscopy
163
(AFM) analysis (Figure 1C). Both curcumin and piperine was efficiently loaded in NPs,
164
achieving an encapsulation efficiency of ~ 65 % (for both drugs) in single or in dual
165
nanoformulation as evident from High performance liquid chromatography (HPLC) analysis.
166
Sustained delivery of the entrapped drug from the NPs represents an important therapeutic
167
advantage, as it lowers the frequency of dosing. In vitro release kinetics study suggested
168
sustained release of both curcumin and piperine from dual drug loaded NPs over a period of 8
169
days (Figure 1D). Both the drugs exhibited a biphasic release pattern with an initial burst
170
(desorption, diffusion and dissolution of drug present at the surface) followed by sustained
171
drug release.
172
In vitro Inhibition of
34
Spherical shape
α-Synuclein Aggregation into Oligomers and Fibrils.
173
Aggregation of αS is a key pathological feature of PD and studies suggest that oligomeric and
174
protofibrillar structures of αS are the toxic entities that sabotage intracellular organelle
175
function, induces oxidative stress thereby leading to neuronal cell death.
176
evidences has shown the potentiality of polyphenols and alkaloids towards inhibition of αS 7 ACS Paragon Plus Environment
35
A series of
ACS Chemical Neuroscience
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
36
Page 8 of 41
177
fibrillation.
In relation to this, the putative role of curcumin in inhibiting αS protein
178
aggregation, thereby protecting neuronal cell death in PD has been documented.
179
recent studies have shown the protective effect of piperine (natural alkaloids) against
180
neuronal injury in PD. 15, 38 However, the effect of piperine on αS protein aggregation has not
181
yet been explored. Therefore in the present study, we have explored the effect of curcumin,
182
piperine and combination of both the drugs on αS protein aggregation into oligomers and
183
fibrils using AFM analysis (Figure 2). Photomicrographs of αS clearly depict the formation
184
of oligomers or long and thin fibrillar structure following incubation of αS protein for 24 hrs
185
and 6 days respectively (Figure 2 and Supporting information, Figure S1A, B). Importantly,
186
co-incubation of αS with curcumin and piperine (native or nanoformulations) both in single
187
as well as in combination resulted in formation of aggregates of smaller size as compared to
188
αS oligomers formed without any drug treatment (Figure 2A and Supporting information
189
Figure S1A). The efficiency of disruption into smaller size was higher for drug loaded NPs
190
than respective native drugs. Noteworthy, combination of curcumin and piperine elucidated
191
more profound inhibition of oligomeric aggregation compared to single counterpart and dual
192
drug loaded NPs exhibited still more inhibitory effect. Further, anti-fibrillar activity of the
193
above formulations was also elucidated from AFM images (Figure 2B and Supporting
194
information, Figure S1B), showing disruption of long fibrillar structure to small oligomeric
195
morphology and more or less it was found that dual drug loaded NPs inhibits the fibril
196
formation profoundly than other formulations. In a recent study conducted by Ahsan et al. the
197
anti-aggregation property of native curcumin have been well documented and similar kind of
198
results was observed, thus corroborating our findings. 37 Importantly, our results also indicate
199
the anti-aggregation property of piperine alone (in native or in NPs) however, the mechanism
200
by which piperine inhibits the aggregation of αS protein remains to be elucidated. The
201
inhibitory effect of piperine and curcumin on αS aggregation was further validated by
8 ACS Paragon Plus Environment
37
Further,
Page 9 of 41
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
ACS Chemical Neuroscience
202
Thioflavin T (ThT) binding assays. Our result demonstrates a higher ThT fluorescence signal
203
in case of oligomeric and fibrillar form of αS. However, co-treatment with curcumin or
204
piperine or combination of both drugs (native or NPs) resulted in lower fluorescence
205
intensity, suggesting the successful inhibition of oligomerization and fibrillation event
206
(Supporting information, Figure S1C). Noteworthy, combinational drug treatment resulted in
207
more profound inhibition and dual drug loaded NPs exhibited significant inhibitory effect
208
than other treatments. In a recent study, Ahmad et al. have documented that curcumin can
209
completely inhibit oligomerization and fibrillation by performing ThT assay, thus
210
substantiating our observation with curcumin. 39
211
Cellular Uptake Study. Cellular uptake of the drug loaded NPs are essential for
212
attaining ample drug level to elicit a substantial therapeutic response. In this regard, exploring
213
the intrinsic fluorescence property of curcumin, an in vitro cellular uptake analysis was
214
performed using fluorescence spectrophotometer and confocal microscopy. The quantitative
215
uptake study by fluorescence spectrophotometer clearly reveals significant uptake of
216
curcumin nanoparticles (CNPs) (~ 8 fold higher uptake at 1hr and 2 hrs time point, ~ 16 fold
217
higher uptakes at 4 hrs time point) compared to native curcumin in PC12 cells (Figure 3A). In
218
a similar study, Wang et al. demonstrated a time dependent enhanced uptake of rhodamine B
219
loaded PLGA NPs in MG-63 cancer cells.
220
comparison to native curcumin was further evident from confocal microscopy results and
221
substantiates the observation of quantitative uptake study (Figure 3B). The higher uptake of
222
CNPs may be realized from the fact that, drug loaded NPs enters the cells by endocytic
223
pathway, while internalization of free drugs occurs through passive diffusion process and
224
reaches saturation after reaching certain concentration inside the cells.
225
enhanced uptake efficiency of CNPs may also have resulted due to the fact that, drug loaded
226
nanoformulations can prevent endolysosomal degradation of drug, thereby increasing its
40
Enhanced intracellular uptake of CNPs in
9 ACS Paragon Plus Environment
41
Additionally, the
ACS Chemical Neuroscience
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
33
Page 10 of 41
227
concentration to several folds.
In comparison, free drug in solution is vulnerable towards
228
lysosomal degradation and as a result may not be sufficiently accumulated inside the cells. 42
229
In vitro Cellular Cytotoxicity Assay. Previous studies have reported that, exposure
230
of dopaminergic cells such as PC12 cells, SH-S5Y cells to neurotoxin rotenone (a
231
mitochondrial Complex I inhibitor) causes oxidative damage, promote the accumulation and
232
aggregation of αS protein thereby accurately imitating many aspect of PD pathogenesis and
233
cell death. Herbal drugs like curcumin and piperine have shown promising results in
234
protecting the dopaminergic cells from rotenone induced cytotoxicity.
235
therapeutic potential of combination of both the drugs in protecting rotenone induced toxicity
236
has not been explored till date. Therefore, to assess the effect of curcumin or piperine or
237
combination of both drugs on rotenone induced toxicity, cell viability study by 3-(4,5-
238
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was performed in PC12
239
cells. The cytotoxicity study with rotenone reveals a dose dependency with 2 µg/ml of
240
rotenone causing approximately 50 % of cell death (Supporting information, Figure S2).
241
Further, to test the protective effect of curcumin or/and piperine on rotenone induced toxicity,
242
we exposed the PC12 cells with rotenone (2 µg/ml) along with various concentration of
243
curcumin, piperine or combination of both the drugs in native or in nanoformulations. All the
244
drug treatments (in native or in NPs) protected against rotenone induced cells death to a
245
substantial extent in a dose dependent manner and drug loaded NPs exhibited superlative
246
protection compared to native counterparts (Figure 4). Importantly combination of curcumin
247
and piperine in nanoparticles revealed profound protection against rotenone induced toxicity
248
than other formulations. The superior protective efficacy of drug loaded NPs in comparison
249
to respective free drug may be attributed to the enhanced cellular internalization and
250
sustained drug release property exhibited by NPs.
10 ACS Paragon Plus Environment
38, 43
However,
Page 11 of 41
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
ACS Chemical Neuroscience
251
Measurement of Intracellular Oxidative Stress. Accumulating evidence advocates
252
that oxidative damage and mitochondrial impairment contributes to the cascade of processes
253
leading to degeneration of dopaminergic neurons in PD.
254
suggest that the decreased level of potent antioxidant Gluathione (GSH) (directly quenches
255
reactive hydroxyl free radicals) in the substantia nigra of PD patients, thus portraying the
256
putative role of this antioxidant in PD pathogenesis.
257
explored the effect of curcumin and piperine either alone or in combination in restoring GSH
258
level. Result depicts a significant reduction in cellular GSH level in rotenone treated PC12
259
cells compared to untreated control cells (Supporting information, Figure S3A). Study
260
conducted by Sharma et al. documented the inhibitory effect of rotenone induced GSH in
261
vivo, thus corroborating our observation.
262
curcumin and piperine (native or NPs) (single or in combination) attenuated GSH depletion
263
induced by rotenone. Note to mention that, combinational drug treatment (curcumin plus
264
piperine) in native and NPs resulted in more profound inhibition and dual drug loaded NPs
265
exhibited superior effect than other treatments. The enhanced restoration of GSH in
266
combinational drug treatment may have resulted owing to the combined antioxidant property
267
exhibited by both curcumin and piperine.
268
regulated by Nrf2
269
Since we have observed an increase GSH level on treatment with curcumin in dual drug
270
loaded NPs (Supporting information, Figure S3A) we anticipate that it might have occurred
271
because of an activated Nrf2. Lipid peroxidation is a key feature in the pathogenesis of PD
272
where reactive oxygen species (ROS) readily attacks the polyunsaturated fatty acid of
273
membrane lipids resulting in significant neuronal cells damage.
274
peroxidation with potent antioxidants like curcumin and piperine may seem to be clinically
275
beneficial.
15
50
47
46
44, 45
In this context diverse studies
Therefore in the present study, we
Importantly, administration of antioxidants like
48, 49
GSH synthesis and utilization is directly
and curcumin is known to up regulates Nrf2 against oxidative stress.
52
51
Therefore alleviating lipid
Our result depicts an augmented lipid peroxidation (as evident from increased
11 ACS Paragon Plus Environment
ACS Chemical Neuroscience
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
276
formation of Thiobarbituric acid reactive substances (TBARS) a by product of lipid
277
peroxidation) in cells treated with rotenone and co-treatment with curcumin and/or piperine
278
(single or in combination) in native or in NPs resulted in substantial reduction of lipid
279
peroxidation (Supporting information, Figure S3B). Noteworthy, combinational drug
280
treatment in NPs exhibited a paramount effect that other treatments following enhanced
281
cellular internalization and synergistic antioxidant activity imparted by both the drugs.
282
Induction of Autophagy-Lysosome Function. Autophagy-lysosome pathway (ALP)
283
is a vital mechanism for the removal of abnormal and aggregated proteins and ample of
284
evidences suggest an impairment in this pathway which thereby aggravate the disease
285
progression.
286
formation) and Lamp2 (lysosomal marker) through western blot analysis following different
287
treatments (Figure 5A). Results indicate a remarkable enhancement in expression of LC3 II
288
and Lamp2 protein following co-treatment with curcumin and/or piperine (in single or
289
combination) in native or in NPs. Importantly, dual drug loaded NPs exhibited augmented
290
expression of both the proteins compared to other treatments, suggesting the potentiality of
291
dual drug loaded NPs in activation of ALP. The restoration of autophagy activity is further
292
authenticated by immunofluorescence analysis of LC3 II in transiently transfected PC12 cells
293
with RFP-LC3 followed by different treatments in combination with rotenone. Result shows
294
few puncta formation i.e. conversion of cytosolic LC3-I to membrane bound LC3-II in
295
rotenone treated cells. However, a significant increase in RFP-LC3 puncta was observed in
296
rotenone treated PC12 cells co-administered with curcumin and/or piperine (both in single as
297
well as in combination) in native or in NPs. Importantly, dual drug loaded NPs exhibited
298
higher puncta formation compared to other treatments thereby suggesting the profound
299
autophagic inducing activity in case of dual drug loaded NPs (Figure 5B). Accumulating
300
evidences strongly suggest αS protein as a major structural component of Lewy bodies (the
53
We therefore, studied the expression of LC3 II (a marker of autophagosome
12 ACS Paragon Plus Environment
Page 12 of 41
Page 13 of 41
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
ACS Chemical Neuroscience
301
pathological hallmark of PD) and narrates the crucial role of this protein in pathogenesis of
302
PD.
303
treatment in cultured PC12 cells, indicating impairment in protein degradation.
304
investigated the effect of curcumin and piperine on αS protein in PC12 cells. Our result
305
showed increase accumulation of αS protein in rotenone treated cells (Figure 5A).
306
Importantly, co-administration with curcumin and/or piperine (single or in combination) in
307
native or in NPs effectively inhibited the rotenone induced accrual of αS with dual drug
308
loaded NPs eliciting more profound effect (Figure 5A). In a recent study by Jiang et al.
309
curcumin efficiently reduced accumulation of A53T αS protein by recovering the
310
macroautophagy process, thereby suggesting the therapeutic role of the drug in ameliorating
311
the neurodegenerative pathology of PD.
312
induce autophagy therefore, an enhanced autophagic activity following a combinational drug
313
treatment both in native as well as NPs might have resulted due to the synergistic action of
314
both the drugs.
315
induced cytotoxicity, cells were exposed to an autophagy inhibitor 3-Methyladenine (3MA)
316
along with rotenone and different concentration of curcumin and piperine in combination (in
317
native or in NPs) for 48 hrs. Results showed that on addition of 3MA the drugs could not
318
protect the cells from rotenone induced cytotoxicity clearly indicating that autophagy plays a
319
crucial role in protecting the PC12 cells from cell death (Figure 5C).
35
Further, Wu et al. recently reported an increased expression of αS on rotenone
56
55
54
We thus
Since, both curcumin and piperine are known to
To further confirm the protective role of autophagy against rotenone
320
Modulation of Apoptosis. Apoptosis is known to play a crucial role in the loss of
321
neurons in PD and deregulated mitochondrial function (a characteristic feature of PD)
322
implicates significantly towards induction of apoptotic response.
323
we have examined a panel of anti-apoptotic and pro-apoptotic proteins related to
324
mitochondrial function. In the present study, we have examined the effect of curcumin and
325
piperine on these proteins by western blotting and result indicates a substantial decrease in 13 ACS Paragon Plus Environment
57
Therefore, in our study,
ACS Chemical Neuroscience
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
326
the protein ratio of Bcl-2 to BAX (Figure 6A and 6B) and an increase in cleaved caspase 3
327
and cleaved PARP expression in rotenone treated PC12 cells, thus marking the prevalence of
328
apoptosis (Figure 6C and 6D). However, an increase in Bcl-2: BAX ratio and decrease in
329
cleaved caspase 3 and cleaved PARP expression was observed in rotenone exposed cells co-
330
administered with curcumin and piperine in combination (in native or in NPs) compared to
331
only rotenone treatment, thus suggesting the role of drugs in combination towards eliciting a
332
survival mechanism. Importantly, dual drug loaded NPs exhibited more profound effect
333
compared to other treatments following enhanced cellular internalization. The study of
334
apoptosis was further validated through flow cytometry, where clear induction of apoptosis
335
(both early as well as late apoptosis) was observed in rotenone treated cells as compared to
336
control group. However, when treated in combination with curcumin and piperine both in
337
native as well as in nanoformulation protected from apoptosis induced by rotenone (Figure
338
6E and 6F) suggesting the activation of cell survival pathway.
339
Enhanced Plasma Bioavailability and Brain Biodistribution of Dual Drug
340
Loaded NPs. Poor bioavailability of curcumin is a major impediment towards therapeutic
341
success of this novel molecule in preclinical settings. To this end Shoba et al. have explored
342
piperine as a bioavailability enhancer and documented superior enhancement in the
343
bioavailability of curcumin in preclinical studies and studies conducted on human volunteers.
344
14
345
bioavailability of curcumin.
346
curcumin in lipid based NPs to enhance the bioavailability of curcumin in plasma to achieve
347
a therapeutic dose in the brain to combat PD. Further, lipid based NPs may also aid towards
348
crossing BBB (owing to lipophilic nature and nanometer size) to deliver the payload in an
349
enhanced way at the site of action. Our in vivo result indicates a low bioavailability (in
350
plasma) (Figure 7A) and low biodistribution (in brain) (Figure 7B) of native curcumin
Further numerous researchers have exploited novel nano-delivery systems to increase 58
In the present investigation, we explored piperine along with
14 ACS Paragon Plus Environment
Page 14 of 41
Page 15 of 41
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
ACS Chemical Neuroscience
351
administered orally, at all the time point studied. Further, the amount of curcumin decreased
352
in a time dependent manner. The lower bioavailability of native curcumin may have resulted
353
due to poor aqueous solubility, degradation under alkaline conditions, limited gastrointestinal
354
absorption and pre-systemic transformation to glucornides in the liver leading to faster
355
elimination.
356
mg/kg orally administered curcumin) was documented by Yang et al. thus, corroborating our
357
observation with native curcumin.
358
piperine (in native or in NPs) resulted in significant enhanced bioavailability and distribution
359
of curcumin in brain tissue compared to only curcumin treatment. The enhanced
360
bioavailability of curcumin might have resulted due to the inhibitory effect of piperine on
361
hepatic and intestinal glucoronidation process (that causes curcumin metabolic degradation).
362
14
363
curcumin in plasma as well as its distribution in brain tissue compared to respective native
364
counterpart. The improved efficacy in drug loaded NPs might have resulted due to better
365
solubility of curcumin in nanoformulation and BBB crossing ability of lipid based NPs. In
366
accordance with our observation, in a recent study Ramalingam et al. have shown the
367
improved oral bioavailability and brain biodistribution of curcumin loaded with N-trimethyl
368
chitosan coated solid lipid NPs compared to native drug.
369
loaded NPs elucidated superlative bioavailability and brain biodistribution of curcumin than
370
other treatment that could be due to combined approach of using piperine and lipid based
371
NPs. As our drug loaded NPs exhibited prolonged plasma retention and augmented
372
bioavailability and enhanced brain tissue distribution of curcumin, we anticipated a
373
substantial delivery of our dual drug loaded NPs to the substatia nigra region of brain. To
374
endorse the above view, uptake of NPs in substantia nigra of brain was evaluated by confocal
375
microscopy (Figure 7C). The confocal microscopy images of the mid brain section clearly
10
Low bioavailability of native curcumin in plasma (0.06 ± µg/ml) of rat (500
59
Importantly, co-administration of curcumin with
Further, encapsulation of drug in NPs significantly enhanced the bioavailability of
60
Note to mention, that dual drug
15 ACS Paragon Plus Environment
ACS Chemical Neuroscience
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
376
indicates the presence of CNPs or CPNPs in the substantia nigra region as evident from green
377
fluorescence of curcumin, thus narrating the putative role of our lipid based NPs in crossing
378
BBB to deliver the therapeutic payload efficiently. NPs have shown remarkable potentiality
379
as a brain targeting system compared to native drugs. In relation to this, in a recent study
380
Kakkar et al. have shown the brain targeting and BBB crossing ability of lipid based NPs to
381
deliver curcumin to the brain, thus substantiating with our observation of enhanced brain
382
targeting with lipid based NPs. 61
383
Restoration of Functional Deficits in a Rotenone Induced Mouse Model of PD.
384
Resting tremor, bradykinesia, muscular rigidity and postural instability are the cardinal
385
manifestations of PD. Therefore, therapeutic molecule that imparts a symptomatic relief in
386
PD may consider beneficial. In the present study, curcumin and piperine has shown
387
substantial therapeutic benefits in preclinical testing by modulating various molecular and
388
biochemical aspects of pathogenesis of PD therefore, we next focused to explore the utility of
389
curcumin and/or piperine loaded NPs in providing functional relief in a rotenone induced
390
mouse model of PD. 62 This model exhibits key symptomatic features of PD (impaired motor
391
balance and coordination) as evident from rotarod motor performance study in which mice
392
treated with rotenone spent less time in the rod compared to untreated control (Figure 8A).
393
Importantly, rotenone induced mice co-administered with curcumin and piperine in
394
combination (native or NPs) showed significant extension of time spent on the rod, with dual
395
drug loaded NPs exhibiting significant effect than native counterpart. These results suggest
396
the potent role of drug combination, specifically dual drug loaded NPs in ameliorating motor
397
dysfunction in rotenone induced PD model. The motor coordination restoration observed with
398
dual drug combination in an enhanced way, can be explained by considering the putative role
399
of both curcumin and piperine in modulating various molecular and biochemical aspects of
400
pathogenesis of PD in vitro observed in the present investigation. Further, the superlative 16 ACS Paragon Plus Environment
Page 16 of 41
Page 17 of 41
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
ACS Chemical Neuroscience
401
efficacy of dual drug loaded NPs over native drug combination may have resulted following
402
enhanced plasma bioavailability, superior brain targeting by crossing BBB, increased
403
delivery to substantia nigra of brain and augmented cellular internalization. In a recent study,
404
da Rocha Lindner et al. have demonstrated the superlative protective efficacy of resveratrol
405
(RVT)-loaded polysorbate 80 (PS80)-coated poly(lactide) nanoparticles compared to native
406
resveratrol in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induces PD model, thus
407
suggesting the advantage of NPs over native drug in neuroprotection.
408
dopaminergic neurons is another cardinal sign of pathogenesis of PD. We therefore further
409
tried to evaluate the effect of curcumin and piperine in protecting the degeneration of
410
dopaminergic neurons in rotenone induced PD mice. As the gold standard marker in the
411
identification of dopaminergic neurons is tyrosine hydroxylase (TH), the rate limiting enzyme
412
in dopamine synthesis, we studied the presence of TH positive neurons to mark the presence
413
of dopaminergic neuronal cells. 16 Immunohistochemistry study of the substantia nigra region
414
clearly indicates low density of TH positive neurons in rotenone treated mice compared to
415
untreated control (Figure 8B, C). Noteworthy, co-administration of curcumin and piperine (in
416
native or NPs) resulted in higher density of TH positive neurons, with dual drug loaded NPs
417
exhibiting more intense effect in protecting against rotenone induced degeneration of
418
dopaminergic neurons.
419
CONCLUSIONS
420
In the present study, we have formulated a dual drug (curcumin and piperine) loaded lipid
421
based nanoformulation and studied its anti parkinsonism effect through various in vitro and in
422
vivo studies. Our present data demonstrate the neuroprotective effect of our dual drug loaded
423
NPs by inhibiting the aggregation of αS protein, reducing the cytotoxicity and oxidative
424
stress induced by rotenone, activation of autophagy mediated protein degradation and
425
induction of anti-apoptotic events. However, a detail investigation on primary target of these 17 ACS Paragon Plus Environment
63
Degeneration of
ACS Chemical Neuroscience
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 18 of 41
426
drugs to ameliorate PD pathogenesis is warranted in near future. Further, the drug loaded NPs
427
also significantly reversed the neurobehavioral abnormalities and neuronal degeneration in
428
the substantia nigra in a PD mice model. The better therapeutic effect of curcumin and
429
piperine in dual drug loaded NPs may be due to improved bioavailability of curcumin, ability
430
to cross BBB and synergistic effect exhibited by both the drugs. Thus, the present study
431
suggest towards the potentiality of our dual drug loaded NPs in ameliorating Parkinson’s
432
pathogenesis in clinical settings.
433
434
METHODS
435
Materials. CUR-500, containing curcumin (> 95 %), was purchased from UNICO
436
Pharmaceuticals (Ludhiana, India). GMO was purchased from Eastman (Tennessee, USA).
437
Sodium chloride and piperine were obtained from MP Biomedicals (Illkirch, France).
438
Acetonitrile was purchased from Spectrochem, India. Dimethyl sulphoxide (DMSO),
439
Methanol, Ethanol and Acetic acid were procured from E-merk (Mumbai, India).
440
Haematoxylin was obtained from Thermo Fisher Scientific, Mumbai, India. Lipofectamine®
441
2000 transfection reagent, Nerve Growth Factor (NGF Mouse protein, Native, 7S subunit)
442
was purchased from Invitrogen Corp. (CA, USA). Skimmed milk powder was procured from
443
Himedia Laboratories Pvt. Ltd., Mumbai, India. mRFP-LC3 (plasmid # 21075) was obtained
444
from Addgene Inc. (MA, USA). Sodium deoxycholate, Ethylene glycol-bis (2 amino ethyl
445
ether)-N, N, N, N-tetraacetic acid (EGTA), Ethylene diamine tetra acetic acid (EDTA), 5,5' -
446
dithiobis-2-nitrobenzoic
447
polyethylene glycol 1000 succinate (vitamin E-TPGS), 3-(4,5-dimethylthiazol-2-yl)-2,5-
448
diphenyltetrazolium bromide (MTT), Pluronic F-68, Polyethylene glycol (PEG)-10,000,
449
Phenylmethylsulfonyl
acid
fluoride
(DTNB),
Poly-L-lysine,
(PMSF),
Sodium
Vitamin
E
orthovanadate
18 ACS Paragon Plus Environment
D-α-Tocopherol
(NaVO4),
β-
Page 19 of 41
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
ACS Chemical Neuroscience
450
glycerophosphate, Protease inhibitor cocktail, Thiobarbituric acid (TBA), Butylated
451
hydroxytoluene (BHT), L-Glutathione reduced, Thioflavin T, Sodium dodecyl sulphate
452
(SDS), 4',6-diamidino-2-phenylindole (DAPI) were obtained from Sigma Aldrich (St. Louis,
453
MO, USA). All other chemicals used were purchased from Sigma Aldrich (St. Louis, MO,
454
USA) without further purification.
455
Preparation of Drug Loaded Lipid Based NPs. Dual drug loaded NPs was 25
456
formulated by following our previous published protocol with little modifications.
457
50 mg of curcumin and 50 mg of piperine was dispersed in fluid phase of GMO (500 µl at 40
458
°C) and vortexed. The above mixture was subjected to emulsification with 10 ml of Pluronic
459
F- 68 solution (5 % w/v) by sonication using a microtip probe sonicator (VC 505, Vibracell
460
Sonics, MA, USA) set at an amplitude of 30 % for 2 mins in an ice bath. The resultant
461
solution was further emulsified with 10 ml of vitamin E-TPGS (5 % w/v) as mentioned
462
above. The above emulsion obtained was centrifuged at 1,000 rpm for 1 min to remove the
463
unentrapped curcumin/piperine, followed by addition of PEG-10,000 (20 mg/ml) as a
464
lyoprotectant with constant vortexing for 5 mins.
465
six days (-50 °C and < 0.05 mBar, Labconco Free Zone 12, Labconco Corporation, Kansas,
466
USA) to obtain the lyophilized powder for further use. Single drug loaded NPs
467
(curcumin/piperine) was also formulated following the above protocol.
64
Briefly,
Finally the emulsion was lyophilized for
468
Physico-Chemical Characterization of Dual Drug Loaded NPs. The particle size
469
and zeta potential of the NPs was measured by Zetasizer (Nano ZS, Malvern Instruments,
470
Malvern, UK) using our previously published protocol.
471
NPs was further assessed by TEM and AFM respectively following our previously published
472
protocol.
473
estimated by reverse phase isocratic mode of RP-HPLC (Waters
474
USA). Briefly, ~ 1 mg/ml of curcumin NPs (CNPs) / piperine NPs (PNPs) or (curcumin and
34
65
Size and surface topology of the
Entrapment efficiency of curcumin and piperine in drug loaded NPs was
19 ACS Paragon Plus Environment
TM
600, Waters Co., MA,
ACS Chemical Neuroscience
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
475
piperine) loaded NPs (CPNPs) was dissolved in ACN, sonicated for 2 min at an amplitude of
476
30 % in an ice bath and the supernatant was collected following centrifugation. Curcumin
477
concentration was measured using the mobile phase ACN: sodium acetate buffer (20 mM, pH
478
3.0): methanol in a ratio of 6:1:3 at a wavelength of 420 nm and piperine was measured using
479
the mobile phase ACN: potassium dihydrogen phosphate (25 mM, pH 4.5) in a ratio of
480
6.5:3.5 at a wavelength of 345 nm.
481
the peak area correlated to a standard curve prepared in an identical condition. In vitro release
482
kinetics of (curcumin and piperine) loaded NPs were performed in PBS as per previously
483
published protocol. 25 All analysis was performed in triplicates.
484
66, 67
The amount of drug in the NPs was obtained from
α-Synuclein Aggregation Assay. α-synuclein aggregation analysis was performed 68
485
following the protocol of Danzer et al.
In brief, stock solution of purified αS (Sigma-
486
Aldrich, St. Louis, MO, USA) was prepared in distilled water and subsequent dilutions were
487
made in 50 mM sodium phosphate buffer (pH 7). Oligomeric forms of αS were generated by
488
dissolving 10 µM of the protein in reaction buffer (50 mM sodium phosphate buffer,
489
containing 20 % ethanol and 10 µM of FeCl3) at room temperature under continuous shaking
490
with overnight incubation while predominantly fibrillar forms of αS were generated by
491
following the same condition with the incubation time increased up to 6 days. Further, to
492
evaluate the inhibitory effect of curumin and piperine on αS aggregation, 10 µM of the
493
protein dissolved in reaction buffer was co-incubated with 7.5 µg/ml of curcumin or piperine
494
(in single or in combination) both in native as well as in nanoformulations and kept in
495
shaking condition overnight (oligomer study) or 6 days (fibrillar study). Following incubation
496
period, the morphology of αS with different treatments was visualized by AFM analysis. For
497
this, ~ 10 µl aliquot of each sample was applied onto freshly cleaved mica surface and left to
498
dry at room temperature for 10 min. Samples were then rinsed with Milli Q water and dried
499
under nitrogen flow. Samples were imaged in contact mode set at a frequency of 13 kHz and
20 ACS Paragon Plus Environment
Page 20 of 41
Page 21 of 41
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
ACS Chemical Neuroscience
500
scanned at a speed of 1 Hz. Topographic images were analyzed and height distribution plot
501
was generated using JPK data processing software. Experiment was performed in triplicates
502
and representative images have been provided.
503
Cell Culture. Rat PC12 cell line was obtained from National Centre for Cell Sciences
504
Cell Repository, Pune, India. Cells were cultured in RPMI media supplemented with 10 %
505
heat inactivated horse serum, 5 % fetal bovine serum (FBS), 1 % L-glutamine and 1 %
506
penicillin-streptomycin (Himedia Laboratories Pvt. Ltd., Mumbai, India) and maintained at
507
37 °C in a 5 % CO2 atmosphere incubator (Hera Cell, Thermo scientific, Waltham, USA). All
508
chemicals for cell culture were purchased from PAN Biotech (GmbH, Germany) unless
509
mentioned. All the cellular experiments were performed in differentiated PC12 cells,
510
obtained by culturing the cells in RPMI media containing NGF (50 ng/ml) and 1 % FBS for 3
511
days and used subsequently for further experiments.
512
Cellular Uptake Study. Quantitative and qualitative cellular uptake of native
513
curcumin and curcumin loaded NPs in PC12 cells were evaluated by fluorescence
514
spectrophotometer and confocal microscopy respectively following our previously published
515
protocol. 25 For quantitative cellular uptake study, 1 × 105 PC12 cells seeded in poly-L-lysine
516
coated twelve well plates (Corning Inc., NY, USA) were treated with 2 µg/ml of native
517
curcumin or equivalent concentration of curcumin loaded NPs for different time points and
518
intracellular concentration of curcumin was quantified using fluorescence spectrophotometer
519
(Ex: 420 nm, Em: 525 nm). Experiments were performed in triplicates. For qualitative
520
cellular uptake study, cells were exposed to above drug treatments for 2 hrs and
521
counterstained with propidium iodide for nuclear staining. Images were visualized in
522
confocal laser scanning microscope (Leica TCS SP5, Leica Microsystems GmbH, Germany)
523
equipped with an argon laser with an FITC filter (Ex: 488 nm, Em: 525 nm) and PI filter (Ex:
21 ACS Paragon Plus Environment
ACS Chemical Neuroscience
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 22 of 41
524
535 nm, Em: 617 nm). The images were processed using Leica Application Suite software.
525
Experiment was performed in triplicates and representative image has been provided.
526
In Vitro Cell Viability Assay. Cell viability was analyzed using MTT based 69
527
colorimetric assay as described in our previously published protocol.
528
seeded at a density of 5 × 103 cells per well in a poly-L-lysine coated 96 well plate (Corning
529
Inc., NY, USA) was treated with different concentration of rotenone (2 µg/ml) or co-treated
530
with rotenone (2 µg/ml) along with different concentration of curcumin or piperine (single or
531
in combination) in native as well as in NPs for 48 hrs. Cells treated with only media was used
532
as control for the experiment. At the end of the incubation period cell viability was assessed
533
by MTT assay. Data represented as mean ± S.E.M (n = 4).
534
Briefly, PC12 cells
Western Blot Analysis. Western blot analysis of different proteins in PC12 cells 34
535
following various treatments was carried out following previously published protocol.
536
Briefly, PC12 cells (1 × 106 cells) seeded in poly-L-lysine coated T-25 flask was exposed to
537
rotenone (2 µg/ml) or co-administered with rotenone (2 µg/ml) along with curcumin or
538
piperine (2 µg/ml, in single or in combination) both in native as well as in nanoformulations.
539
After 48 hrs of treatment, the cells were harvested, washed with PBS and whole cell lysate
540
was prepared with RIPA buffer. Western blot analysis of various proteins were performed
541
using specific primary antibody recognizing LC3 (Novus Biologicals, Colorado, USA), α-
542
synuclein, Lamp2, β-actin (Santa Cruz Biotechnology, Inc., CA, USA), BAX, Bcl-2, PARP,
543
Caspase 3 (Cell Signaling Technology, Inc., MA, USA) and their respective secondary
544
antibody. The band intensity was measured by ImageJ software.
545
Fluorescence Imaging of Red Fluorescent Protein (RFP) LC3 for Autophagy
546
Study. The RFP-LC3 transfected PC12 cells were generated by transfecting pRFP-LC3
547
plasmid into subconfluent PC12 cells using Lipofectamine® 2000 transfection kit.
548
PC12 cells at density of 1 × 106 were seeded in 60 x 15 mm petridish (Corning, NY, USA)
22 ACS Paragon Plus Environment
70
Briefly,
Page 23 of 41
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
ACS Chemical Neuroscience
549
for overnight attachment. Next day, 8 µg of plasmid DNA was mixed with 20 µl of
550
Lipofectamine® 2000 reagent in serum free RPMI media, incubated for 20 mins at room
551
temperature and then added to the cells. After 8 hrs of incubation, the transfection media was
552
replaced with fresh culture medium. Next day, RFP-LC3 transfected PC12 cells were seeded
553
at a density of 1 × 105 cells in poly-L-lysine coated coverslips. The cells were then
554
differentiated with 50 ng/ml NGF media for 3 days. The cells were then treated for 48 hrs
555
with rotenone (2 µg/ml) or co-administered with rotenone (2 µg/ml) along with curcumin or
556
piperine (2 µg/ml, in single or in combination) both in native as well as in nanoformulations.
557
After 48 hrs, the cells were washed with PBS and fixed with 4 % paraformaldehyde. Cells
558
were again washed with PBS incubated with DAPI to stain the nucleus and finally mounted
559
with aqueous mounting media (Vector Laboratories, California, USA) and observed under
560
confocal microscopy (Leica TCS SP5, Leica Microsystems, Germany) for the formation of
561
RFP-LC3 puncta, a primary marker of autophagosomes formation. Further, the effect of
562
impaired autophagosome pathway on cell cytotoxicity, cellular viability was assessed in
563
PC12 cells treated with 3MA (autophagosome inhibitor). In brief, 5 × 103 PC12 cells seeded
564
in 96 well plates were treated with 3MA (10 mM), rotenone (2 µg/ml) and different
565
concentration of curcumin and piperine in combination (in native or in NPs) for 48 hrs and
566
cell viability was assessed by MTT assay as mentioned before.
567
Apoptosis Study. Apoptotic cell death in PC12 cells following different treatments 34
Briefly, 3 x 105
568
was studied by flow cytometry following previously published protocol.
569
PC12 cells seeded in six well plates were treated with rotenone (2 µg/ml) or co-administered
570
with rotenone (2 µg/ml) along with curcumin and piperine (2 µg/ml in combination) in native
571
as well as in nanoformulations for 48 hrs. Cells treated with only media served as control for
572
the experiment. After the incubation period, cells were washed thrice with PBS and processed
573
for apoptosis analysis using Annexin V-PE and 7-aminoactinomycin D (7-AAD) (BD
23 ACS Paragon Plus Environment
ACS Chemical Neuroscience
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
574
FACSCalibur Flow Cytometer, BD Biosciences, CA, USA) in FL2-H and FL3-H channel
575
respectively using FlowJo software.
576
In vivo Study. Male Balb/c mice and male C57BL/6 mice were used for different in
577
vivo experiments with the approval of the Institutional Animal Ethics committee of the
578
Institute of Life Sciences, Bhubaneswar. The animals were housed at a constant temperature
579
and relative humidity with alternating 12-hr cycles of light and dark. Mouse was housed in
580
standard laboratory cages and had free access to food and water throughout the study period.
581
For the pharmacokinetics study animals were fasted overnight before dosing.
582
In vivo Bioavailability Study. Male Balb/c mice (4–6 weeks old), weighing 22 ± 10
583
g, were divided into five groups (n = 3). Group 1: control, administered with 0.5 %
584
carboxymethyl cellulose sodium salt (CMC). Group 2: administered with native curcumin
585
dispersed in 0.5 % CMC at a dose of 100 mg/kg body weight, Group 3: administered with
586
CNPs dispersed in distilled water at an equivalent dose of native curcumin (100 mg/kg body
587
weight). Group 4: administered with native curcumin and piperine (1:1 ratio) dispersed in 0.5
588
% CMC at a dose of 100 mg/kg body weight. Group 5: administered with CPNPs dispersed
589
in distilled water at an equivalent dose of (curcumin and piperine) native of 100 mg/kg body
590
weight. After oral administration by gavage with a catheter at different time points (0.5, 2, 6,
591
48 hrs) blood samples were collected from retro-orbital plexus into pre-coated heparin tubes.
592
Curcumin concentration in plasma was estimated by HPLC as mentioned before using the
593
protocol of Shaikh et al.
594
biodistribution analysis was carried out at the above time points for all the five groups.
595
Briefly, the brain was dissected out at different time points, homogenized with PBS (BD-144
596
Tissue Homogeniser, BD Bioscience, Haryana, India) and lyophilized. The lyophilized
597
samples were processed for estimation of curcumin present in brain tissue by HPLC using
598
previously published protocol. 67
67
To study the amount of curcumin present in the brain tissue,
24 ACS Paragon Plus Environment
Page 24 of 41
Page 25 of 41
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
ACS Chemical Neuroscience
599
Immunofluorescence. Male Balb/c mice (4–6 weeks old), weighing 22 ± 10 g were
600
divided into five group (n = 3) as mentioned above. The mice were administered with the
601
above treatments for 2 hrs. Following treatment, transcardial perfusion was performed with 4
602
% paraformaldehyde (pH 7.4) under deep anesthesia with xylazine and ketamine. After
603
perfusion, the brain was quickly removed and post fixed in 4 % paraformaldehyde solution at
604
4 °C overnight. Post fixed mid brain region was trimmed out and were embedded in paraffin,
605
followed by preparation of multiple coronal sections (5 µm) using a microtome. Slides
606
containing paraffin embedded brain sections were deparaffinized with xylene and rehydrated
607
by ethanol with concentration gradient of 100-70 % followed by washing with water. The
608
slides were then boiled in antigen retrieval solution for 20 min and were allowed to cool
609
down at room temperature. The sections were then washed with PBS containing 0.1 % Tween
610
20 (PBST), and then blocked with 2.5 % horse serum for 1 hr at 37 °C. After blocking,
611
sections were incubated with a rabbit polyclonal anti-TH antibody (1: 200 dilutions)
612
overnight at 4 °C. After a 10 min rinse in PBST, the sections were incubated with anti-rabbit
613
IgG secondary antibody Alexa Fluor® 594 conjugate (Invitrogen Corp., CA, USA) for 45
614
min. Finally the sections were washed with PBST and mounted with aqueous mounting
615
media and fluorescence (green for curcumin and red for TH positive cells) was observed
616
under confocal microscope (Leica TCS SP5, Leica Microsystems, GmbH, Germany).
617
Animal Model. Male, 8-10 weeks old C57BL/6 mice (25-30g) were randomly
618
assigned to 5 groups (n = 4). Group 1: control, administered orally with 0.5 % CMC as a
619
vehicle once daily for 28 days; Group 2: administered orally with rotenone suspended in 0.5
620
% CMC, once daily at a dose of 30 mg/kg body weight for 28 days; Group 3: administered
621
orally with native curcumin and native piperine (1:1 ratio) at a dose of 200 mg/kg body
622
weight, every alternate day, 30 min before administration of rotenone. Group 4: administered
623
orally with CPNPs at an equivalent dose of 200 mg/ kg body weight, every alternate day, 30
25 ACS Paragon Plus Environment
ACS Chemical Neuroscience
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
624
min before administration of rotenone. Group 5: administered orally with void NPs at an
625
equivalent dose of 200 mg/kg body weight every alternate day 30 min before administration
626
of rotenone. At the end of the experiment, on 29th day, the mice were preceded to rotarod task
627
for monitoring the behavioral pattern of mice and further studied the presence of
628
dopaminergic neurons (TH positive) in brain tissue through immunohistochemistry.
629
Motor Performance Study. The behavior of each mouse was assessed by the rotarod 62
630
test, as described by Inden et al.
by using rotarod treadmill (Orchid Scientific and
631
Innovative India Pvt Ltd, Nashik, India). In the present study, mice (from all groups of
632
treatment along with control) were placed on the rod rotating at 20 rpm, and the falling
633
latencies were recorded for up to 250 sec. All mice were tested on 29th day after the initial
634
rotenone administration.
635
Immunohistochemistry. In brief, transcardial perfusion was performed with 4 %
636
paraformaldehyde (pH 7.4) under deep anesthesia with xylazine and ketamine. The brain was
637
collected and multiple coronal sections (5 µm) were obtained using a microtome. Slides
638
containing paraffin embedded brain sections were deparaffinized with xylene and rehydrated
639
by ethanol with concentration gradient of 100-70 % followed by washing with water. The
640
slides were then boiled in antigen retrieval solution for 20 mins and were allowed to cool
641
down at room temperature followed by washing with PBST. Sections were then incubated
642
with 3 % hydrogen peroxide for 15 min at room temperature to remove the endogenous
643
peroxidase activity and then blocked with 2.5 % horse serum for 1 hr at 37 °C. After blocking
644
for 1 hr, sections were incubated with a rabbit polyclonal anti-TH antibody (1:200 dilutions,
645
Millipore, Darmstadt, Germany) overnight at 4 °C. After a 10 min rinse in PBST, the sections
646
were incubated with biotinylated secondary universal horse anti-rabbit/mouse IgG
647
(Vectastain Kit; Vector Laboratories, California, USA) for 45 mins, followed by incubation
648
with avidin-biotin peroxidase complex for 30 mins at room temperature. Sections were
26 ACS Paragon Plus Environment
Page 26 of 41
Page 27 of 41
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
ACS Chemical Neuroscience
649
washed with PBST and exposed to diaminobenzidine (DAB) and the photographs of the brain
650
sections were taken using phase contrast microscope (Leica EZ, UK) with 40 X objective and
651
then TH positive neurons were counted. A certified human pathologist evaluated all the
652
stained slides.
653
Statistics: Results are expressed as mean ± S.E.M. or mean ± SD. Statistical analysis
654
of the data was performed by applying student’s t-test, one way and two way ANOVA using
655
GraphPad Prism Software and values of p < 0.05 were indicative of significant differences.
656
Supporting Information: Histogram analysis of oligomers and fibrils obtained from
657
AFM study; Dose dependent cytotoxicity of rotenone in PC12 cells; Cellular GSH and lipid
658
peroxidation assay.
659
AUTHOR INFORMATION
660
Corresponding Author
661
*Sanjeeb K Sahoo, Ph.D
662
Laboratory for Nanomedicine,
663
Institute of Life Sciences,
664
Nalco Square, Chandrasekharpur,
665
Bhubaneswar, Orissa, INDIA
666
Phone- 91-674-2302094
667
Fax- 91-674-2300728
668
E-mail-
[email protected] 669
Author Contributions
670
Conceived and designed the project P.K and S.K.S. Performed the experiments P.K and M.D.
671
Analyzed the data P.K, M.D, K.T and S.K.S. Contributed to the preparation of manuscript
672
P.K, M.D and S.K.S
673 27 ACS Paragon Plus Environment
ACS Chemical Neuroscience
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
674
Notes
675
The authors declare no competing financial interest.
676
ACKNOWLEDGEMENTS
677
P.K. acknowledges University Grants Commission (UGC), New Delhi, India for providing
678
the award of Junior Research Fellowship (JRF). S.K.S and P.K. acknowledge Dr. Rupesh
679
Dash, Scientist at Institute of Life Sciences and lab members for experimental help in
680
autophagy study. S.K.S and P.K are also thankful to Dr. Shantibhusan Senapati, Scientist at
681
Institute of Life Sciences and lab members for their help in in vivo studies. Technical help of
682
Mr. Priyadarshi Ray in AFM and Mr. Madan Mallick for histological sectioning is
683
acknowledged.
684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 28 ACS Paragon Plus Environment
Page 28 of 41
Page 29 of 41
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
ACS Chemical Neuroscience
699 700 701 702 703 704
705 706 707 708 709 710 711
Figure 1. Physicochemical characterization of dual drug loaded NPs. (A) Size of (curcumin and piperine)
712
loaded NPs (CPNPs) as measured by dynamic laser light scattering. (B) Transmission electron micrograph of
713
CPNPs, depicting that the formulated particles are of nanometer size range. Inset shows a higher magnification
714
of the particle. (C) AFM image of CPNPs, depicting their smooth and spherical topology. All experiments were
715
performed in triplicates and representative image has been provided. (D) In vitro release kinetics of curcumin
716
and piperine from dual drug loaded NPs as percent of drug release. Data represented as mean ± S.E.M (n = 3).
717 718 719 720 721 722 723 724 725 726
29 ACS Paragon Plus Environment
ACS Chemical Neuroscience
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
727
A
Oligomer
VNPs
CN
PN
PNPs
CPN
Fibrils
VNPs
CN
PN
PNPs
CPN
Page 30 of 41
CNPs
728 729 730 731 CPNPs
732 733 734 735
B CNPs
736 737 738 739 CPNPs
740 741 742 743 744 745
Figure 2. Atomic force microscopy analysis to study the aggregation of α-synuclein (αS) protein.
746
Representative AFM images of αS, showing inhibitory effect of different treatments on the formation of (A)
747
oligomers and (B) fibrils. The reaction mixture containing 10 µM αS, 50 mM sodium phosphate buffer pH 7, 20
748
% ethanol and 10 µM FeCl3 were treated with 7.5 µg/ml of native curcumin (CN), native piperine (PN) and
749
combination of native curcumin and native piperine (CPN) or equivalent concentration of curcumin NPs
750
(CNPs), piperine NPs (PNPs) and (curcumin and piperine) NPs (CPNPs), or equivalent amount of void NPs
751
(VNPs) incubated at room temperature under continuous shaking overnight (for oligomer formation) and 6 days
752
(for fibril formation). Experiment has been performed in triplicates and representative image has been provided.
753 754 755 756 30 ACS Paragon Plus Environment
Page 31 of 41
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
ACS Chemical Neuroscience
757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772
Figure 3. In vitro cellular uptake study. (A) Quantitative cellular uptake study of CN and CNPs in PC12 cells
773
for different time period by fluorescence spectrophotometer (Ex: 420 nm, Em: 525 nm). Data are presented as
774
mean ± SEM (n = 3). ***p < 0.001 CNPs in comparison to CN. (B) Qualitative cellular uptake analysis of CN
775
and CNPs in PC12 cells at 2 hr time point by confocal microscope equipped with FITC filter (Ex: 488 nm, Em:
776
525 nm) and with PI filter (Ex: 535 nm, Em: 617 nm). Experiment has been performed in triplicates and
777
representative image has been provided.
778 779 780 781 782 783 784 785 786 787
31 ACS Paragon Plus Environment
ACS Chemical Neuroscience
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
788 789 790 791 792 793 794 795 796 797 798 799 800 801 802
Figure 4. Cytotoxicity study to assess the protective effect of different treatments on rotenone induced
803
cytotoxicity in PC12 cells for 48 hrs by MTT assay. Cells were co-incubated with various concentrations of the
804
drug with 2 µg/ml rotenone (R) and cellular viability was determined. Results are presented as mean ± S.E.M (n
805
= 4). p< 0.05 is considered significant. ###p corresponds to rotenone vs control and *p **p or ***p corresponds
806
to different treatments vs rotenone. 1. CN, 2. CNPs, 3.PN, 4.PNPs, 5.CPN, 6.CPNPs, 7.VNPs.
807 808 809 810 811 812 813 814 815 816
32 ACS Paragon Plus Environment
Page 32 of 41
Page 33 of 41
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
ACS Chemical Neuroscience
817 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 834 835 836 837 838 839
Figure 5. (A) Western blot analysis was performed to investigate the expression of LC3 II, Lamp 2, α-synuclein
840
proteins following different treatments in PC12 cells. Cells were co-treated with R (2 µg/ml) along with 2 µg/ml
841
of CN, PN, CPN and CNPs, PNPs and CPNPs for 48 hrs. 1. Control, 2. R, 3.(R + CN), 4.(R + CNPs), 5. (R +
842
PN), 6.(R + PNPs), 7.(R + CPN), 8.(R + CPNPs). (B) Study of autophagy in PC12 cells through confocal
843
microscope. In brief, cells were transfected with RFP-LC3 plasmid and exposed to above treatments for 48 hrs.
844
Cells exhibiting RFP-LC3 puncta (indicator of autophagosome formation) were observed under confocal
845
microscope. Experiment has been performed in triplicates and representative image has been provided. (C)
846
Investigating the effect of autophagy inhibition towards protective effect of different treatments on rotenone
847
induced cytotoxicity in PC12 cells. In brief, cells were exposed to R (2 µg/ml) or 10 mM of 3MA and R (2
848
µg/ml) or co-administered with 10 mM 3MA, R (2 µg/ml) and different concentration of (curcumin and
849
piperine) in native or in NPs for 48 hrs and cell viability was assessed by MTT assay. Data presented as mean ±
850
S.E.M (n = 4). p< 0.05 is considered significant. **p or ***p corresponds to treatment with inhibitor and drug
851
treatment vs with only drug treatment.
33 ACS Paragon Plus Environment
ACS Chemical Neuroscience
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 877 878
Figure 6. Study of apoptosis. (A) Representative immunoblots of Bcl2 and BAX expression and (B)
879
quantification of Bcl2/ BAX. (C) Representative immunoblot of apoptotic protein Caspase 3. (D) Representative
880
immunoblot of apoptotic protein PARP. 1. Control, 2. R, 3.(R + CPN), 4.(R + CPNPs). (E) Analysis of
881
apoptosis by flow cytometry to study the protective effect of CPN or CPNPs against rotenone induced apoptosis
882
in PC12 cells for 48 hrs and apoptosis percentage was analyzed by annexin V-PE and 7-AAD staining.
883
Experiment has been performed in triplicates and representative image has been provided. (F) Bar diagram
884
depicting total percentage of apoptotic cells. p< 0.05 is considered significant. ###p corresponds to rotenone vs
885
control and ***p corresponds to different treatment vs rotenone.
886 887 888
34 ACS Paragon Plus Environment
Page 34 of 41
Page 35 of 41
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
ACS Chemical Neuroscience
889 890
B
A
891 892 893 894 895 C
896
CN
CPN
CNPs
CPNPs
897 898 899 900 901 902 903 904 905 906 907 908 909
Figure 7. Pharmacokinetics of curcumin in mice (A) plasma (B) brain tissue after single oral administration of
910
CN, CNPs, CPN and CPNPs at a dose of 100 mg/kg body weight. Values are presented as mean ± S.E.M (n =
911
3). *p < 0.05, **p < 0.01, or ***p < 0.001 for CN vs CPNPs; #p or ##p or ###p corresponds to CPN vs CPNPs.
912
(C) Histological sections of the substantia nigra region of brain tissues (marked by immunoexpression for TH,
913
red) showing efficient accumulation of curcumin (green) after 2 hrs oral treatment and representative image has
914
been provided (n = 3). Insets are the higher magnification of area showing the presence of CNPs and CPNPs
915
(white arrow).
916 917 918 919 920 921 922 923 924 925 35 ACS Paragon Plus Environment
ACS Chemical Neuroscience
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957
Figure 8. Effect of different drug treatments on rotenone induced (A) behavioral deficit in mice as assessed by
958
rotarod and (B) representative image of TH positive neurons in the substantia nigra region of the brain following
959
different treatments has been provided (black arrow). (C) TH positive neurons count per field to study the
960
dopaminergic neuronal cell death in the substantia nigra. Data are presented as mean ± SEM (n = 4). p< 0.05 is
961
considered significant. ###p corresponds to rotenone vs control and *p or ***p corresponds to different
962
treatment vs rotenone and •••p corresponds to CPN vs CPNPs. Experiment has been performed with n = 4
963
animals.
964 965 966
REFERENCES
36 ACS Paragon Plus Environment
Page 36 of 41
Page 37 of 41
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015
ACS Chemical Neuroscience
[1] Moore, D. J., West, A. B., Dawson, V. L., and Dawson, T. M. (2005) Molecular pathophysiology of Parkinson's disease, Annu. Rev. Neurosci. 28, 57-87. [2] Gandhi, S., and Wood, N. W. (2005) Molecular pathogenesis of Parkinson's disease, Hum. Mol. Genet. 14, 2749-2755. [3] Dauer, W., and Przedborski, S. (2003) Parkinson's disease: mechanisms and models, Neuron 39, 889-909. [4] Connolly, B. S., and Lang, A. E. (2014) Pharmacological treatment of Parkinson disease: a review, Jama 311, 1670-1683. [5] Meissner, W. G., Frasier, M., Gasser, T., Goetz, C. G., Lozano, A., Piccini, P., Obeso, J. A., Rascol, O., Schapira, A., Voon, V., Weiner, D. M., Tison, F., and Bezard, E. (2011) Priorities in Parkinson's disease research, Nat. Rev. Drug Discov. 10, 377-393. [6] Chaudhuri, K. R., Rizos, A., and Sethi, K. D. (2013) Motor and nonmotor complications in Parkinson's disease: an argument for continuous drug delivery?, J. Neural Transm. 120, 1305-1320. [7] Rajeswari, A., and Sabesan, M. (2008) Inhibition of monoamine oxidase-B by the polyphenolic compound, curcumin and its metabolite tetrahydrocurcumin, in a model of Parkinson's disease induced by MPTP neurodegeneration in mice, Inflammopharmacology 16, 96-99. [8] Rajeswari, A. (2006) Curcumin protects mouse brain from oxidative stress caused by 1methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Eur. Rev. Med. Pharmacol. Sci. 10, 157-161. [9] Zbarsky, V., Datla, K. P., Parkar, S., Rai, D. K., Aruoma, O. I., and Dexter, D. T. (2005) Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson's disease, Free Radic. Res. 39, 1119-1125. [10] Anand, P., Kunnumakkara, A. B., Newman, R. A., and Aggarwal, B. B. (2007) Bioavailability of curcumin: problems and promises, Mol. Pharm. 4, 807-818. [11] Singh, S., Jamwal, S., and Kumar, P. (2015) Piperine Enhances the Protective Effect of Curcumin Against 3-NP Induced Neurotoxicity: Possible Neurotransmitters Modulation Mechanism, Neurochem. Res. 8, 1758-1766. [12] Panahi, Y., Khalili, N., Hosseini, M. S., Abbasinazari, M., and Sahebkar, A. (2014) Lipid-modifying effects of adjunctive therapy with curcuminoids-piperine combination in patients with metabolic syndrome: results of a randomized controlled trial, Complement. Ther. Med. 22, 851-857. [13] Ucisik, M. H., Kupcu, S., Schuster, B., and Sleytr, U. B. (2013) Characterization of CurcuEmulsomes: nanoformulation for enhanced solubility and delivery of curcumin, J. Nanobiotechnology 11, 37. [14] Shoba, G., Joy, D., Joseph, T., Majeed, M., Rajendran, R., and Srinivas, P. S. (1998) Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers, Planta Med. 64, 353-356. [15] Shrivastava, P., Vaibhav, K., Tabassum, R., Khan, A., Ishrat, T., Khan, M. M., Ahmad, A., Islam, F., Safhi, M. M., and Islam, F. (2013) Anti-apoptotic and anti-inflammatory effect of Piperine on 6-OHDA induced Parkinson's rat model, J. Nutr. Biochem. 24, 680-687. [16] Al-Baghdadi, O. B., Prater, N. I., Van der Schyf, C. J., and Geldenhuys, W. J. (2012) Inhibition of monoamine oxidase by derivatives of piperine, an alkaloid from the pepper plant Piper nigrum, for possible use in Parkinson's disease, Bioorg. Med. Chem. Lett. 22, 71837188. [17] Patel, T. R. (2014) Nanocarrier-based therapies for CNS tumors, CNS Oncol. 3, 115-122. [18] Dilnawaz, F., and Sahoo, S. K. (2015) Therapeutic approaches of magnetic nanoparticles for the central nervous system, Drug Discov. Today 20, 1256-1264.
37 ACS Paragon Plus Environment
ACS Chemical Neuroscience
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
1016 1017 1018 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 1030 1031 1032 1033 1034 1035 1036 1037 1038 1039 1040 1041 1042 1043 1044 1045 1046 1047 1048 1049 1050 1051 1052 1053 1054 1055 1056 1057 1058 1059 1060 1061 1062 1063
[19] Kaur, I. P., Bhandari, R., Bhandari, S., and Kakkar, V. (2008) Potential of solid lipid nanoparticles in brain targeting, J. Control. Release 127, 97-109. [20] Wong, H. L., Chattopadhyay, N., Wu, X. Y., and Bendayan, R. (2010) Nanotechnology applications for improved delivery of antiretroviral drugs to the brain, Adv. Drug Deliv. Rev. 62, 503-517. [21] Uner, M., and Yener, G. (2007) Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives, Int. J. Nanomedicine 2, 289-300. [22] Lai, J., Lu, Y., Yin, Z., Hu, F., and Wu, W. (2010) Pharmacokinetics and enhanced oral bioavailability in beagle dogs of cyclosporine A encapsulated in glyceryl monooleate/poloxamer 407 cubic nanoparticles, Int. J. Nanomedicine 5, 13-23. [23] Yang, Z., Chen, M., Yang, M., Chen, J., Fang, W., and Xu, P. (2014) Evaluating the potential of cubosomal nanoparticles for oral delivery of amphotericin B in treating fungal infection, Int. J. Nanomedicine 9, 327-336. [24] Dilnawaz, F., Singh, A., Mewar, S., Sharma, U., Jagannathan, N. R., and Sahoo, S. K. (2011) The transport of non-surfactant based paclitaxel loaded magnetic nanoparticles across the blood brain barrier in a rat model, Biomaterials 33, 2936-2951. [25] Parhi, P., and Sahoo, S. K. (2015) Trastuzumab guided nanotheranostics: A lipid based multifunctional nanoformulation for targeted drug delivery and imaging in breast cancer therapy, J. Colloid. Interface Sci. 451, 198-211. [26] Kreuter, J. (2004) Influence of the surface properties on nanoparticle-mediated transport of drugs to the brain, J. Nanosci. Nanotechnol. 4, 484-488. [27] Kulkarni, S. A., and Feng, S. S. (2013) Effects of particle size and surface modification on cellular uptake and biodistribution of polymeric nanoparticles for drug delivery, Pharm. Res. 30, 2512-2522. [28] Gelperina, S., Maksimenko, O., Khalansky, A., Vanchugova, L., Shipulo, E., Abbasova, K., Berdiev, R., Wohlfart, S., Chepurnova, N., and Kreuter, J. (2010) Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: influence of the formulation parameters, Eur. J. Pharm. Biopharm. 74, 157-163. [29] Kalia, L. V., Kalia, S. K., and Lang, A. E. (2015) Disease-modifying strategies for Parkinson's disease, Mov. Disord. 30, 1442-1450. [30] Garbayo, E., Ansorena, E., and Blanco-Prieto, M. J. (2013) Drug development in Parkinson's disease: from emerging molecules to innovative drug delivery systems, Maturitas 76, 272-278. [31] Jain, K. K. (2012) Nanobiotechnology-based strategies for crossing the blood-brain barrier, Nanomedicine (Lond.) 7, 1225-1233. [32] Grau, C. M., and Greene, L. A. (2012) Use of PC12 cells and rat superior cervical ganglion sympathetic neurons as models for neuroprotective assays relevant to Parkinson's disease, Methods Mol. Biol. 846, 201-211. [33] Panyam, J., Zhou, W. Z., Prabha, S., Sahoo, S. K., and Labhasetwar, V. (2002) Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery, Faseb J. 16, 1217-1226. [34] Das, M., Duan, W., and Sahoo, S. K. (2015) Multifunctional nanoparticle-EpCAM aptamer bioconjugates: a paradigm for targeted drug delivery and imaging in cancer therapy, Nanomedicine 11, 379-389. [35] Stefanis, L. (2012) alpha-Synuclein in Parkinson's disease, Cold Spring Harb. Perspect. Med. 2, a009399. [36] Ono, K., and Yamada, M. (2006) Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro, J. Neurochem. 97, 105-115.
38 ACS Paragon Plus Environment
Page 38 of 41
Page 39 of 41
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
1064 1065 1066 1067 1068 1069 1070 1071 1072 1073 1074 1075 1076 1077 1078 1079 1080 1081 1082 1083 1084 1085 1086 1087 1088 1089 1090 1091 1092 1093 1094 1095 1096 1097 1098 1099 1100 1101 1102 1103 1104 1105 1106 1107 1108 1109 1110 1111 1112 1113
ACS Chemical Neuroscience
[37] Ahsan, N., Mishra, S., Jain, M. K., Surolia, A., and Gupta, S. (2015) Curcumin Pyrazole and its derivative (N-(3-Nitrophenylpyrazole) Curcumin inhibit aggregation, disrupt fibrils and modulate toxicity of Wild type and Mutant alpha-Synuclein, Sci. Rep. 5, 9862. [38] Wang, H., Liu, J., Gao, G., Wu, X., Wang, X., and Yang, H. (2015) Protection effect of piperine and piperlonguminine from Piper longum L. alkaloids against rotenone-induced neuronal injury, Brain Res. 1639, 214-227. [39] Ahmad, B., and Lapidus, L. J. (2012) Curcumin prevents aggregation in alpha-synuclein by increasing reconfiguration rate, J. Biol. Chem. 287, 9193-9199. [40] Wang, B., Yu, X. C., Xu, S. F., and Xu, M. (2015) Paclitaxel and etoposide co-loaded polymeric nanoparticles for the effective combination therapy against human osteosarcoma, J. Nanobiotechnology 13, 22. [41] Sahoo, S. K., and Labhasetwar, V. (2005) Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention, Mol. Pharm. 2, 373-383. [42] Panyam, J., and Labhasetwar, V. (2003) Dynamics of endocytosis and exocytosis of poly(D,L-lactide-co-glycolide) nanoparticles in vascular smooth muscle cells, Pharm. Res. 20, 212-220. [43] Jayaraj, R. L., Tamilselvam, K., Manivasagam, T., and Elangovan, N. (2013) Neuroprotective effect of CNB-001, a novel pyrazole derivative of curcumin on biochemical and apoptotic markers against rotenone-induced SK-N-SH cellular model of Parkinson's disease, J. Mol. Neurosci. 51, 863-870. [44] Schapira, A. H., and Jenner, P. (2011) Etiology and pathogenesis of Parkinson's disease, Mov. Disord. 26, 1049-1055. [45] Zhu, J., and Chu, C. T. (2010) Mitochondrial dysfunction in Parkinson's disease, J. Alzheimers Dis. 20 Suppl 2, S325-334. [46] Martin, H. L., and Teismann, P. (2009) Glutathione--a review on its role and significance in Parkinson's disease, Faseb J. 23, 3263-3272. [47] Sharma, N., and Nehru, B. (2013) Beneficial Effect of Vitamin E in Rotenone Induced Model of PD: Behavioural, Neurochemical and Biochemical Study, Exp. Neurobiol. 22, 214223. [48] Jagatha, B., Mythri, R. B., Vali, S., and Bharath, M. M. (2008) Curcumin treatment alleviates the effects of glutathione depletion in vitro and in vivo: therapeutic implications for Parkinson's disease explained via in silico studies, Free Radic. Biol. Med. 44, 907-917. [49] Lee, C. S., Han, E. S., and Kim, Y. K. (2006) Piperine inhibition of 1-methyl-4phenylpyridinium-induced mitochondrial dysfunction and cell death in PC12 cells, Eur. J. Pharmacol. 537, 37-44. [50] Gorrini, C., Harris, I. S., and Mak, T. W. (2013) Modulation of oxidative stress as an anticancer strategy, Nat. Rev. Drug Discov. 12, 931-947. [51] Liu, Z., Dou, W., Zheng, Y., Wen, Q., Qin, M., Wang, X., Tang, H., Zhang, R., Lv, D., Wang, J., and Zhao, S. (2016) Curcumin upregulates Nrf2 nuclear translocation and protects rat hepatic stellate cells against oxidative stress, Mol. Med. Rep. 13, 1717-1724. [52] Reale, M., Pesce, M., Priyadarshini, M., Kamal, M. A., and Patruno, A. (2012) Mitochondria as an easy target to oxidative stress events in Parkinson's disease, CNS Neurol. Disord. Drug Targets 11, 430-438. [53] Dehay, B., Martinez-Vicente, M., Caldwell, G. A., Caldwell, K. A., Yue, Z., Cookson, M. R., Klein, C., Vila, M., and Bezard, E. (2013) Lysosomal impairment in Parkinson's disease, Mov. Disord. 28, 725-732. [54] Wu, F., Xu, H. D., Guan, J. J., Hou, Y. S., Gu, J. H., Zhen, X. C., and Qin, Z. H. (2015) Rotenone impairs autophagic flux and lysosomal functions in Parkinson's disease, Neuroscience 284, 900-911. 39 ACS Paragon Plus Environment
ACS Chemical Neuroscience
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
1114 1115 1116 1117 1118 1119 1120 1121 1122 1123 1124 1125 1126 1127 1128 1129 1130 1131 1132 1133 1134 1135 1136 1137 1138 1139 1140 1141 1142 1143 1144 1145 1146 1147 1148 1149 1150 1151 1152 1153 1154 1155 1156 1157 1158 1159 1160 1161 1162
[55] Jiang, T. F., Zhang, Y. J., Zhou, H. Y., Wang, H. M., Tian, L. P., Liu, J., Ding, J. Q., and Chen, S. D. (2013) Curcumin ameliorates the neurodegenerative pathology in A53T alphasynuclein cell model of Parkinson's disease through the downregulation of mTOR/p70S6K signaling and the recovery of macroautophagy, J. Neuroimmune Pharmacol. 8, 356-369. [56] Naponelli, V., Modernelli, A., Bettuzzi, S., and Rizzi, F. (2015) Roles of autophagy induced by natural compounds in prostate cancer, Biomed. Res. Int. 2015, 121826. [57] Rekha, K. R., and Selvakumar, G. P. (2014) Gene expression regulation of Bcl2, Bax and cytochrome-C by geraniol on chronic MPTP/probenecid induced C57BL/6 mice model of Parkinson's disease, Chem. Biol. Interact. 217, 57-66. [58] Shakeri, A., and Sahebkar, A. (2015) Nanotechnology: A Successful Approach to Improve Oral Bioavailability of Phytochemicals, Recent Pat. Drug Deliv. Formul.1, 4-6. [59] Yang, K. Y., Lin, L. C., Tseng, T. Y., Wang, S. C., and Tsai, T. H. (2007) Oral bioavailability of curcumin in rat and the herbal analysis from Curcuma longa by LCMS/MS, J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 853, 183-189. [60] Ramalingam, P., and Ko, Y. T. (2015) Enhanced oral delivery of curcumin from Ntrimethyl chitosan surface-modified solid lipid nanoparticles: pharmacokinetic and brain distribution evaluations, Pharm Res 32, 389-402. [61] Kakkar, V., Mishra, A. K., Chuttani, K., and Kaur, I. P. (2013) Proof of concept studies to confirm the delivery of curcumin loaded solid lipid nanoparticles (C-SLNs) to brain, Int. J. Pharm. 448, 354-359. [62] Inden, M., Kitamura, Y., Tamaki, A., Yanagida, T., Shibaike, T., Yamamoto, A., Takata, K., Yasui, H., Taira, T., Ariga, H., and Taniguchi, T. (2009) Neuroprotective effect of the antiparkinsonian drug pramipexole against nigrostriatal dopaminergic degeneration in rotenone-treated mice, Neurochem. Int. 55, 760-767. [63] da Rocha Lindner, G., Bonfanti Santos, D., Colle, D., Gasnhar Moreira, E. L., Daniel Prediger, R., Farina, M., Khalil, N. M., and Mara Mainardes, R. (2015) Improved neuroprotective effects of resveratrol-loaded polysorbate 80-coated poly(lactide) nanoparticles in MPTP-induced Parkinsonism, Nanomedicine (Lond.) 10, 1127-1138. [64] Vandana, M., and Sahoo, S. K. (2009) Optimization of physicochemical parameters influencing the fabrication of protein-loaded chitosan nanoparticles, Nanomedicine (Lond.) 4, 773-785. [65] Misra, R., Das, M., Sahoo, B. S., and Sahoo, S. K. (2014) Reversal of multidrug resistance in vitro by co-delivery of MDR1 targeting siRNA and doxorubicin using a novel cationic poly(lactide-co-glycolide) nanoformulation, Int. J. Pharm. 475, 372-384. [66] Suresh, D., and Srinivasan, K. (2010) Tissue distribution & elimination of capsaicin, piperine & curcumin following oral intake in rats, Indian J. Med. Res. 131, 682-691. [67] Shaikh, J., Ankola, D. D., Beniwal, V., Singh, D., and Kumar, M. N. (2009) Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer, Eur. J. Pharm. Sci. 37, 223-230. [68] Danzer, K. M., Haasen, D., Karow, A. R., Moussaud, S., Habeck, M., Giese, A., Kretzschmar, H., Hengerer, B., and Kostka, M. (2007) Different species of alpha-synuclein oligomers induce calcium influx and seeding, J. Neurosci. 27, 9220-9232. [69] Vandana, M., and Sahoo, S. K. (2015) Synergistic activity of combination therapy with PEGylated pemetrexed and gemcitabine for an effective cancer treatment, Eur. J. Pharm. Biopharm. 83-93. [70] Kimura, S., Noda, T., and Yoshimori, T. (2007) Dissection of the autophagosome maturation process by a novel reporter protein, tandem fluorescent-tagged LC3, Autophagy 3, 452-460.
40 ACS Paragon Plus Environment
Page 40 of 41
Page 41 of 41
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
ACS Chemical Neuroscience
Delivery of dual drug loaded lipid based nanoparticles across blood brain barrier impart enhanced neuroprotection in a rotenone induced mouse model of Parkinson’s disease Paromita Kundu¶, Manasi Das¶, Kalpalata Tripathyǂ, Sanjeeb K Sahoo*, ¶
"Table of Contents Graphic"
ACS Paragon Plus Environment